TP53 and cancer: The p53CKO model (p53R172H/∆E2–10CKO or p53R172HCKO) produced targeted cells with p53 compound heterozygous mutations harboring one p53∆E2–10 null mutation (deleting the entire p53 coding region) and one hotspot missense point mutation p53R172H (homologous to TP53R175H in human cancers) (Fig. 1a and Supplementary Fig. 1b)1.